Cladribine (Mavenclad) for Multiple Sclerosis

Date: July 29, 2019
Issue #: 
1577Summary: 
The FDA has approved cladribine (Mavenclad– EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of M S. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of MS.

Source: The Medical Letter - June 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Cladribine Copaxone dimethyl fumarate Fingolimod Gilenya Glatiramer acetate Interferon beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy siponimod T Source Type: research